ARWR: Dual gene knockdown, strong clinical data, and AI-driven innovation highlight broad pipeline progress
Breakthrough dual gene knockdown was achieved with ARO-DIMER-PA, showing strong efficacy in mixed hyperlipidemia and a clear path to pivotal trials. The plozasiran launch is progressing well, with robust clinical data and a focus on high-risk patients. AI and proprietary RNAi experience drive innov…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.